Scarica l'app Stockscreener
31.80
20.00%
5.30
Dopo l'orario di chiusura:
31.48
-0.32
-1.01%
Precedente Chiudi:
$26.50
Aprire:
$25.03
Volume 24 ore:
5.95M
Relative Volume:
13.73
Capitalizzazione di mercato:
$1.02B
Reddito:
$4.85M
Utile/perdita netta:
$-114.75M
Rapporto P/E:
-9.7846
EPS:
-3.25
Flusso di cassa netto:
$-100.36M
1 W Prestazione:
+34.92%
1M Prestazione:
+69.51%
6M Prestazione:
+32.33%
1 anno Prestazione:
+19.46%
Intervallo 1D:
$25.00
$32.80
Intervallo di 1 settimana:
$23.39
$32.80
Portata 52W:
$13.37
$32.80
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
31.80 | 852.99M | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.25 | 101.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.03 | 59.25B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.44 | 60.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
768.00 | 45.95B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
346.45 | 37.61B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - inkl
Using data filters to optimize entry into Dianthus Therapeutics Inc.July 2025 Opening Moves & Daily Momentum Trading Reports - Newser
Does Dianthus Therapeutics Inc. stock benefit from AI growthJuly 2025 Spike Watch & AI Enhanced Trading Signals - beatles.ru
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline - Benzinga
Evercore ISI Adjusts Dianthus Therapeutics Price Target to $72 From $50, Maintains Outperform Rating - MarketScreener
What momentum shifts mean for Dianthus Therapeutics Inc.Quarterly Profit Report & AI Based Buy/Sell Signal Reports - Newser
Analyzing recovery setups for Dianthus Therapeutics Inc. investorsMarket Movement Recap & Consistent Profit Trading Strategies - Newser
Dianthus Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com Canada
Does Dianthus Therapeutics Inc. show high probability of rebound2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - The Manila Times
Visual analytics tools that track Dianthus Therapeutics Inc. performanceEarnings Growth Summary & Stepwise Swing Trade Plans - Newser
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
How to recover losses in Dianthus Therapeutics Inc. stockBuy Signal & Fast Entry Momentum Alerts - Newser
Using RSI to spot recovery in Dianthus Therapeutics Inc.2025 Market Sentiment & Fast Entry High Yield Tips - Newser
Visual trend scoring systems applied to Dianthus Therapeutics Inc.Index Update & Risk Controlled Daily Trade Plans - Newser
Will Dianthus Therapeutics Inc. stock go up soonJuly 2025 Patterns & Expert Curated Trade Setups - Newser
Dianthus Therapeutics Inc. stock trend forecastChart Signals & Weekly Top Stock Performers List - Newser
Applying Elliott Wave Theory to Dianthus Therapeutics Inc.July 2025 Volume & Low Drawdown Investment Ideas - Newser
Backtesting results for Dianthus Therapeutics Inc. trading strategiesJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
Heatmap analysis for Dianthus Therapeutics Inc. and competitors2025 Top Gainers & Step-by-Step Trade Execution Guides - Newser
Vestal Point Capital LP Grows Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - The Manila Times
Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative
Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan
RA Capital Management L.P. Boosts Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Momentum Indicator Shows Bearish Divergence in Dianthus Therapeutics Inc.Quarterly Earnings Report & Free Real-Time Market Sentiment Alerts - beatles.ru
Ally Bridge Group NY LLC Lowers Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Best data tools to analyze Dianthus Therapeutics Inc. stockJuly 2025 EndofMonth & Precise Swing Trade Entry Alerts - Newser
Combining machine learning predictions for Dianthus Therapeutics Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Technical signs of recovery in Dianthus Therapeutics Inc.Earnings Growth Summary & Free Verified High Yield Trade Plans - Newser
Is this a good reentry point in Dianthus Therapeutics Inc.2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Is it too late to sell Dianthus Therapeutics Inc.Weekly Stock Recap & Stepwise Trade Signal Guides - Newser
Analyzing net buyer seller activity in Dianthus Therapeutics Inc.Portfolio Update Summary & Capital Efficiency Focused Strategies - Newser
Real time scanner hits for Dianthus Therapeutics Inc. explainedMarket Growth Summary & Growth-Oriented Investment Plans - Newser
Should I invest in Dianthus Therapeutics Inc. before earningsJuly 2025 Trends & Free Long-Term Investment Growth Plans - خودرو بانک
Braidwell LP Lowers Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Nuveen LLC Acquires New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Guggenheim reiterates Buy rating on Dianthus Therapeutics stock ahead of data - Investing.com Canada
Does Dianthus Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Safe Entry Point Identification - Newser
Published on: 2025-09-05 02:02:07 - Newser
How to build a dashboard for Dianthus Therapeutics Inc. stockWeekly Market Summary & Advanced Technical Analysis Signals - Newser
Is Dianthus Therapeutics Inc. trending in predictive chart modelsWeekly Gains Summary & Risk Managed Trade Strategies - Newser
Does Dianthus Therapeutics Inc. fit your quant trading modelTrade Volume Report & Daily Market Momentum Tracking - Newser
Published on: 2025-09-04 04:01:28 - Newser
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.75%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):